Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814709 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814182 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815259 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814631 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815012 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815007 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL813431 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814961 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814488 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815197 | 0.86 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978961-B1 | TETRALONE-BASED MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-8053603-B2 | Tetralone-based monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053603-B2 | Tetralone-based monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.